Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04614987 · ClinicalTrials.gov registry record
Serum Neurofilament Light (NfL) as a Marker for Brain Injury in Individuals Undergoing Chimeric Antigen Receptor-modified T Therapy
A clinical trial, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- 17
- Enrollment target
NCT04614987 is a clinical trial that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 17 participants.
The verdict
NCT04614987 was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- 17 participants
- Enrollment target
Study Summary
The investigators propose that immune effector cell-associated neurotoxicity syndrome (ICANS) is predicated upon the early loss of blood brain barrier (BBB) integrity with subsequent monocyte infiltration leading to cross-activation of native glial cells. Glial overstimulation leads to neuroinflammation, synaptic dysfunction, and ultimately neuronal injury.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2021-02-25 |
| Est. Completion | 2023-09-13 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04614987
The ClinicalTrials.gov registry entry for NCT04614987 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04614987 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04614987 about?
NCT04614987 is a clinical study titled "Serum Neurofilament Light (NfL) as a Marker for Brain Injury in Individuals Undergoing Chimeric Antigen Receptor-modified T Therapy". The investigators propose that immune effector cell-associated neurotoxicity syndrome (ICANS) is predicated upon the early loss of blood brain barrier (BBB) integrity with subsequent monocyte infiltration leading to cross-activation of native glial cells. Glial overstimulation leads to neuroinflamma...
What is the current status of trial NCT04614987?
This trial is currently terminated. The enrollment target is 17 participants. The study started on 2021-02-25. Estimated completion is 2023-09-13.
Who is sponsoring clinical trial NCT04614987?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.